Two questions—or two groups of questions. The first one: as a member of the Health Committee—the very hard-working select committee that it is—we started the term with 53 petitions. We have cleared that backlog pretty much, but the bulk of them were about, of course, Pharmac funding particular types of medicines, particularly for people with rare disorders but also for things like cancer; something that has been approved for one use but has the potential to be used for multiple uses. I bear in mind a recent petition, one we're dealing with at the moment, from Carmen Shanks, on cystic fibrosis. I acknowledge her and the work she has done in sharing her stories with us, and also Cystic Fibrosis New Zealand and the advocacy they've done in this area for Trikafta.